NVS NOVARTIS AG IFRS
Pharmaceutical Preparations · NYSE · SEC CIK 1114448 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY8.4%
TTM net income YoY17.1%
TTM EPS YoY21.8%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR26.2%
Margins
Gross margin78.8%
Operating margin32.4%
Net margin25.6%
FCF margin32.3%
EBITDA margin—
Returns
ROE31.0%
ROA13.1%
ROIC (approx.)44.8%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.00x
Current ratio1.12x
Interest coverage15.42x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-4.8%
Payout ratio55.9%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $54.53B | $50.32B | $45.44B | $42.21B | $42.78B |
| Cost of revenue | $13.70B | $12.83B | $12.47B | $11.58B | $11.73B |
| Gross profit | $42.98B | $38.90B | $34.19B | $31.88B | $32.24B |
| R&D expense | $11.20B | $10.02B | $11.37B | $9.17B | $8.64B |
| SG&A expense | $13.25B | $12.57B | $12.52B | $12.19B | $12.83B |
| Operating income | $17.64B | $14.54B | $9.77B | $7.95B | $10.06B |
| Interest expense | $1.14B | $1.01B | $855.00M | $800.00M | $787.00M |
| Pretax income | $16.35B | $13.64B | $9.12B | $7.18B | $24.53B |
| Income tax | $2.38B | $1.70B | $551.00M | $1.13B | $1.62B |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | $24.02B |
| EPS (basic) | 7.21 | 5.92 | 7.15 | 3.19 | 10.71 |
| EPS (diluted) | 7.15 | 5.87 | 7.10 | 3.17 | 10.63 |
| Weighted avg. shares (diluted) | 1.96B | 2.04B | 2.09B | 2.20B | 2.26B |
| Balance sheet | |||||
| Cash & equivalents | $11.44B | $11.46B | $13.39B | $7.52B | $12.41B |
| Short-term investments | $98.00M | $1.89B | $569.00M | $11.09B | $12.96B |
| Receivables | $8.94B | $7.42B | $7.11B | $8.07B | $8.01B |
| Inventory | $6.27B | $5.72B | $5.91B | $7.17B | $6.67B |
| Current assets | $30.46B | $29.70B | $30.48B | $36.91B | $45.72B |
| PP&E, netmay include right-of-use assets (IFRS) | $10.78B | $9.46B | $9.51B | $10.76B | $11.54B |
| Goodwill | $25.57B | $24.76B | $23.34B | $29.30B | $29.59B |
| Intangibles | $29.41B | $26.91B | $26.88B | $31.64B | $34.18B |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | $131.79B |
| Current liabilities | $27.28B | $28.69B | $26.39B | $28.66B | $30.21B |
| Short-term debt | $682.00M | $642.00M | $624.00M | $863.00M | $899.00M |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | $63.97B |
| Shareholders' equity | $46.13B | $44.05B | $46.67B | $59.34B | $67.66B |
| Shares outstanding | 1.91B | 1.98B | 2.04B | 2.12B | 2.23B |
| Cash flow statement | |||||
| Operating cash flow | $19.14B | $17.62B | $14.46B | $14.24B | $15.07B |
| Capital expenditure | $1.55B | $1.37B | $1.06B | $916.00M | $1.07B |
| Free cash flow | $17.60B | $16.25B | $13.40B | $13.32B | $14.01B |
| Investing cash flow | -$4.88B | -$7.51B | $5.60B | $1.47B | $4.21B |
| Financing cash flow | -$14.87B | -$11.74B | -$14.28B | -$20.56B | -$16.26B |
| Stock-based compensation | $1.10B | $1.04B | $865.00M | $791.00M | $700.00M |
| Dividends paid | $7.82B | $7.62B | $7.25B | $7.51B | $7.37B |
| Share buybacks | $9.21B | $8.33B | $8.72B | $10.65B | $3.06B |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.